Treatment strategies for obsessive-compulsive disorder

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 3, 2010, Pages 331-343

  Marazziti, Donatella ^a   Consoli, Giorgio ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Clomipramine; Cognitive behavioral therapy; Deep brain stimulation; Electroconvulsive therapy; Exposure and response prevention; Neurosurgery; Obsessive compulsive disorder; Predictor of response; Repetitive transcranial magnetic stimulation; Resistance

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CYCLOSERINE; CYTOCHROME P450; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; MIRTAZAPINE; MORPHINE; OLANZAPINE; PAROXETINE; PHENELZINE; PINDOLOL; PLACEBO; RILUZOLE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRYPTOPHAN; VENLAFAXINE;

ACCELERATION; ANORGASMIA; BEDTIME DOSAGE; BRAIN DEPTH STIMULATION; BRAIN SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE THERAPY; DISEASE COURSE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; ERECTILE DYSFUNCTION; FATIGUE; HUMAN; INSOMNIA; LIBIDO; LOW DRUG DOSE; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; ONSET AGE; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; RELAPSE; REMISSION; REVIEW; SEDATION; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; SUICIDAL BEHAVIOR; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; CLOMIPRAMINE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEEP BRAIN STIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTRIC STIMULATION THERAPY; ELECTROCONVULSIVE THERAPY; ELECTROSHOCK; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; OBSESSIVE-COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME; VAGUS NERVE;

EID: 76449087603     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903446948     Document Type: Review

References (185)

1. American Psychiatric Association Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 4th edition. American Psychiatric Press; Washington, DC; 1994
2. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988;45(12):1094-1099
3. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
4. Hollander E, Stein D. Obsessive-compulsive disorder. Oxford Press; 1999
5. Merikangas KR. Clinical features of anxiety disorders. In: Kaplan HI, Sadock BJ, editors, Comprehensive textbook of psychiatry. 8th edition. Lippincott Williams & Wilkins; 2004. p. 1104-1126
6. Hollander E, Weilgus-Kornwasser J. Counting the cost- the psychosocial and economic burden of OCD. Focus OCD 1997;5:3-5
7. Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet 2009;374(9688):491-499
8. Fullana MA, Mataix-Cols D, Caspi A, et al. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am J Psychiatry 2009;166(3):329-336
9. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
10. Montgomery SA. Pharmacological treatment of obsessive-compulsive disorder. In: Hollander E, Zohar J, Marazziti D, Oliver B, editors, Current insights in obsessive-compulsive disorder. Chichester, Wiley & Sons; 1994. p. 215-226
11. Greist JH, Jefferson JV, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995;52:53-60
12. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry 1995;166(4):424-443
13. Finiberg N. Refining treatment approaches in obsessive-compulsive disorder. Int Clin Psychopharmacol 1996;11(5):13-22
14. Hoehn-Saric R, Ninan P, Black DW, et al. Multicenter double blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000;57:76-82
15. Zohar J, Chopra M, Sasson Y, et al. Obsessive compulsive disorder: serotonin and beyond. World J Biol Psychiatry 2000;1(2):92-100
16. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol 1996;64:660-668
17. Lopez-IborJJ, Fernandez-Cordobe E. La monclomipramina en-enfermos resistentes a otros tratamiantos. Acta Luso-Espan Neurol Psiquiatria 1967;26:119-147
18. Flament MF, Rapoport JL, Berg CJ, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double blind controlled study. Arch Gen Psychiatry 1985;42:977-983
19. Mavissakalian M, Turner SM, Michelson L, Jacob R. Tricyclic antidepressant in obsessive-compulsive disorder. Antiobsessional or antidepressant agents? Am J Psychiatry 1985;142:301-306
20. Murphy DL, Siever LJ, Insel TR. Therapeutic response to tricyclic antidepressants and related drugs in non affective disorder patient population. Prog Neuro Psychopharmacol Biol Psychiatry 1985;9:3-13
21. Katz RJ, De Veaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990;28:401-414
22. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br Med J 1993;306(6879):683-687
23. Mitchell J, Greenberg J, Finch K, et al. Effectiveness and economic impact of antidepressant medication: a review. Am J Manag Care 1997;3(2):323-330
24. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000;58(1):19-36
25. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacol 1986;90:131-138
26. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect, than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299
27. Montgomery SA, Mc Auley R, Montgomery DB, et al. Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. Postgrad Med J 1980;56(1):130-133
28. Tollefson GD, Rampey AH, Pottvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
29. Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:57-65
30. Montgomery SA, Kasper S, Stein D, et al. Citalopram 20mg, 40mg and 60mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16(2):75-86
31. Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003;64(9):1113-1121 (Pubitemid 37158259)
32. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67:15-22
33. Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008;23:49-53
34. Montgomery SA, McIntyre A, Osterheider M, et al.; Wood AJ and the Lilly Europen OCD Study Group. A double-blind placebo-controlled of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993;3:143-152
35. Zitterl W, Meszaros K, Hornik K, et al. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Clin Wochenschr 1999;111:439-442
36. Romano S, Goodman W, Tamura R, Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001;21:46-52
37. Goodman WK, Price LH, Rasmussen SA, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder. A doubleblind comparison with placebo. Arch Gen Psychiatry 1989;46:36-44
38. Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-29
39. Hohagen F, Winkelmann G, Rasche-Ruchle H, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 1998;35:71-78
40. Milanfranchi A, Ravagli S, Lensi P, et al. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997;12:131-136 (Pubitemid 27283320)
41. Mundo E, Rouillon F, Figuera ML, Stigler M. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum Psychopharmacol 2001;16(6):461-468
42. Cottraux J, Mollard E, Bouvard M, Marks I. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 1993;49:63-75
43. Mallya GK, White K, Waternaux C, et al. Short and long-term treatment of obsessive-compulsive disorder with fluvoxamine. Ann Clin Psychiatry 1992;4:77-80
44. Hollander E, Koran LM, Goodman WK, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003;64(6):640-647
45. Ordacgi L, Mendlowicz MV, Fontenelle LF. Management of obsessive-compulsive disorder with fluvoxamine extended release. Neuropsychiatr Dis Treat 2009;5:301-308
46. Owen RT. Controlled-release fluvoxamine in obsessive-compulsive disorder and social phobia. Drugs Today (Barc) 2008;44(12):887-893
47. Chouinard G, Goodman W, Greist J, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990;26(3):279-284
48. Kronig MH, Apter J, Asnis G, et al. Placebo-controlled, multi-centre study of sertraline study for obsessive-compulsive disorder. J Clin Psychopharmacol 1999;19:172-176
49. Jenike MA, Baer L, Summergrad P, et al. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am J Psychiatry 1990;147(7):923-928
50. Rasmussen SA, Baer L, Shera D. Previous treatment and efficacy of sertraline for OCD: combined analysis of 4 multicenter trials. Annual meeting of the American Psychiatric Association; San Diego, CA; 1997. p. 17-22
51. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
52. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002;12(3):181-186
53. Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002;159:88-95
54. Bergeron R, Ravindran AV, Chaput Y, et al. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-months study. J Clin Psychopharmacol 2002;22:148-154
55. Weadon D, Bushnell WD, Steiner M. A fixed dose comparison of 20, 40, or 60 mg of paroxetine to placebo in the treatment of obsessive-compulsive disorder. The American college of neuropsychopharmacology; Annual Meeting, Puerto Rico; 1993
56. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474
57. White K, Keck PE Jr, Lipinski J. Serotonin-uptake inhibitors in obsessive-compulsive disorder: a case report. Compr Psychiatry 1986;27(3):211-214
58. Marazziti D, Dell'Osso L, Gemignani A, et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 2001;16:215-219
59. Pallanti S, Quercioli L, Koran LM. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 2002;63(9):796-801
60. Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007;23:701-711
61. Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 2007;17:430-439
62. Marazziti D. Venlafaxine treatment of obsessive-compulsive disorder: case reports. CNS Spectr 2003;8(6):421-422
63. Denys D, Van Der Wee N, Van Megen H, Westenberg H. A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23(6):568-575
64. Koran LM, Gamel NN, Choung HW, et al. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005;66:515-520
65. Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004;65:1394-1399
66. Vallejo J, Olivares J, Marcos T, et al. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry 1992;161:665-670
67. Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996;153:1219-1221
68. Storch EA, Merlo LJ, Bengtson M, et al. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007;22:230-237
69. Grant P, Coric V, Taskiran S, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005;58(5):424-428
70. Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007;17(6):761-767
71. Koran LM, Aboujaoude E, Bullock KD, et al. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2005;66:353-359
72. McDougle CJ, Goodman WK, Lechman JF, et al. The psychopharmacology of obsessive-compulsive disorder: implications for treatment and pathogenesis. Psychiatry Clin North Am 1993;16:749-766
73. Marazziti D, Catena M, Pallanti S. Pharmacological treatment of obsessive-compulsive disorder. Psychiatry Ann 2006;36(7):454-462
74. Marazziti D, Mungai F, Vivarelli L, Dell'Osso B. Critical issues in the pharmacological treatment of obsessive-compulsive disorder. Clin Neuropsychiatry 2004;1:59-64
75. Bandelow PB, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry 2008;9(4):248-312
76. Mattes J. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int Clin Psychopharmacol 1986;1:170-173
77. Simeon JC, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990;26:285-290
78. Browne M, Horn E, Jones TT. The benefits of Clomipramine-fluoxetine combination in obsessive-compulsive disorder. Can J Psychiatry 1993;38:242-243
79. Marazziti D, Golia F, Consoli G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 2008;13(11):971-976
80. Dannon PN, Sasson Y, Hirschmann S, et al. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000;10:165-169
81. Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998;13:219-224
82. Van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006;23:1-5
83. McDougle CJ, Goodman WK, Leckman JF, et al. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994;51:302-308
84. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SSRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
85. McDougle CJ, Epperson CN, Pelton GH, et al. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801
86. Hollander E, Rossi NB, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003;6(4):397-401 (Pubitemid 38146258)
87. D'Amico G, Cedro C, Muscatello MR, et al. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(4):619-623
88. Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000;96(2):91-98
89. Shapira NA, Ward HE, Mandoki M, et al. A double-blind, placebo-controlled trial of oloanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004;55(5):553-555
90. Marazziti D, Pfanner C, Dell'Osso B, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol 2005;19:392-394
91. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 2008;18:364-372
92. Atmacha M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17(3):115-119
93. Denys D, De Geus F, Van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004;65:1040-1048
94. Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SSRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005;20:223-226
95. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002;17:37-40
96. Sevincok L, Topuz A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23(5):448-450
97. Pessina E, Albert U, Bogetto F, Maina G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int Clin Psychopharmacol 2009;24(5):265-269
98. Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-632 (Pubitemid 43989810)
99. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93
100. Koran LM, Aboujaoude E, Ward H, et al. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2006;26:79-83
101. Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the art treatment. J Clin Psychiatry 2002;63(6):20-29
102. Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropharmacol 2002;5:181-191
103. Mundo E, Bareggi SR, Pirola R, et al. Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: is gender a predictive variable? Biol Psychiatry 1999;45:290-294
104. Steiner M, Gergel IP, Wheadon DE. Predictors of response to paroxetine therapy in OCD. Annual Meeting of the American Psychiatric Association, Toronto; 1996; May 20-25
105. Stein DJ, Montgomery SA, Kasper S, Tanghoj P. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:357-361
106. Erzegovesi S, Cavallini MC, Cavedini P, et al. Clinical predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 2001;21:488-492
107. Ackerman DL, Greenland S, Bystritsky A, et al. Predictors of treatment response in obsessive-compulsive disorder: multivariate analyses from a multicenter trial of clomipramine. J Clin Psychopharmacol 1994;14:247-254
108. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998;18:185-192
109. Steketee G, Eisen J, Dyck I, et al. Predictors of course in obsessive-compulsive disorder. Psychiatry Res 1999;27:229-238
110. Ravizza L, Barzega G, Bellino S, et al. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry 1995;56:368-373
111. Ackerman DL, Greenland S, Bystritsky A. Use of receiver-operator characteristic (ROC) curve analysis to evaluate predictors of response to clomipramine therapy. Psychopharmacol Bull 1996;32:157-165
112. Rosario-Campos MC, Leckman JF, Mercadante MT, et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry 2001;158:1899-1903
113. Ronchi P, Abruzzese M, Erzegovesi S, et al. The epidemiology of obsessive-compulsive disorder in an Italian population. Eur Psychiatry 1992;7:53-59
114. Leckman JF, Grice DE, Boardman J, et al. Symptoms of obsessive-compulsive disorder. Am J Psychiatry 1997;154:911-917
115. Mataix-Cols D, Rauch SL, Manzo PA, et al. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Am J Psychiatry 1999;156:1409-1416
116. Angst J. The epidemiology of obsessive compulsive disorder. In: Hollander E, Zohar J, Marazziti D, Olivier B, editors, Current insights in obsessive compulsive disorder. John Wiley & Sons, Inc.; New York, NY; 1994. p. 93-104
117. Denys D, Burger H, Van Megen H, et al. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2003;18:315-322
118. Mataix-Cols D, Wooderson S, Lawrence N, et al. Distinct neural correlates of washing, checking, and hoarding symptom dimensions in obsessive-compulsive disorder. Arch Gen Psychiatry 2004;61:564-576
119. Baer L. Factor analysis of symptom subtypes of obsessive compulsive disorder and their relation to personality and tic disorders. J Clin Psychiatry 1994;55:18-23
120. Alonso P, Menchon JM, Pifarre J, et al. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. J Clin Psychiatry 2001;62:535-540
121. Black DW, Monahan P, Gable J, et al. Hoarding and treatment response in 38 nondepressed subjects with obsessive-compulsive disorder. J Clin Psychiatry 1998;59:420-425
122. Jenike MA, Baer L, Minichello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-1264
123. Baer L, Rauch SL, Ballantine HT, et al. Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 1995;52:384-392
124. Ball SG, Baer L, Otto MW. Symptom subtypes of obsessive-compulsive disorder in behavioral treatment studies: a quantitative review. Behav Res Ther 1996;34:47-51
125. Buchanan AW, Ko SM, Marks IM. What predicts improvement and compliance during the behavioral treatment of obsessive compulsive disorder? Anxiety 1996;2:22-27
126. Alarcon RD, Libb JW, Spitler D. A predictive study of obsessive-compulsive disorder response to clomipramine. J Clin Psychopharmacol 1993;13:210-213
127. Phillips KA. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin 1998;62:33-48
128. Winsberg ME, Cassic KS, Koran LM. Hoarding in obsessive-compulsive disorder: a report of 20 cases. J Clin Psychiatry 1999;60:591-597
129. Zitterl W, Lenz G, Mayrhofer A, Zapotoczky HG. Obsessive-compulsive disorder: course and interaction with depression: a review of the literature. Psychopathology 1990;23:73-80
130. Skoog G, Skoog J. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1999;56:131-132
131. Catapano F, Sperandeo R, Perris F, et al. Insight and resistance in patients with obsessive-compulsive disorder. Psychopathology 2001;34:62-68
132. Ravi KV, Samar R, Reddy YCJ, et al. Clinical characteristics and treatment response in poor and good insight obsessive-compulsive disorder. Eur Psychiatry 2004;19:202-208
133. Eisen JL, Rasmussen SA, Phillips KA, et al. Insight and treatment outcome in obsessive-compulsive disorder. Compr Psychiatry 2001;42:494-497
134. Matsunaga H, KiriikeN, Matsui T, et al. Obsessive-compulsive disorder with poor insight. Compr Psychiatry 2002;43:150-157
135. Ackerman DL, Greenland S, Bystritsky A, Katz RJ. Relationship between early side effects and therapeutic effects of clomipramine therapy in OCD. J Clin Psychopharmacol 1996;16:324-328
136. Ackerman DL, Greenland SMS, Bystritsky A. Side effects as predictors of drug response in obsessive-compulsive disorder. J Clin Psychopharmacol 1999;19:459-465
137. Post RM, Weiss SR. Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders: the role of serotonergic mechanisms in illness progression. Biol Psychiatry 1998;44:193-206
138. Mundo E, Bellodi L, Smeraldi E. Effects of acute intravenous clomipramine on obsessive-compulsive symptoms and response to chronic treatment. Biol Psychiatry 1995;38:525-531
139. Sallee FR, Koran LM, Pallanti S, et al. Intravenous clomipramine challenge in obsessive-compulsive disorder: predicting response to oral therapy at eight weeks. Biol Psychiatry 1998;44:220-227
140. Hollander E, Cohen LJ, DeCaria C, et al. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Biol Psychiatry 1993;15:407-413
141. Koran LM, Pallanti S, Quercioli L. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. Eur Neuropsychopharmacol 2001;11:169-172
142. Marks IM, Hodgson R, Rachman S. Treatment of chronic obsessive-compulsive neurosis by in vivo exposure. Br J Psychiatry 1975;127:349-364
143. Foa EB, Steketee G, Milby JB. Differential effects of exposure and response prevention in obsessive-compulsive washers. J Consult Clin Psychol 1980;48:71-79
144. Foa EB, Steketee G, Grayson JB, Latimer PR. Deliberate exposure and blocking of obsessive-compulsive rituals: immediate and long-term effects. Behav Ther 1984;15:450-472
145. Castle DJ, Deale A, Marks IM, et al. Obsessive-compulsive disorder: prediction of outcome from behavioural psychotherapy. Acta Psychiatr Scand 1994;89(6):393-398
146. Perse T. Obsessive-compulsive disorder: a treatment review. J Clin Psychiatry 1988;49(2):48-55
147. Steketee G, Cleere L. Obsessional-compulsive disorder. In: Bellak AS, Hersen M, Kazdin EA, editors, International handbook of behavior modification and therapy. Plenum Press; New York; 1990. p. 307-332
148. Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997;65(1):44-52
149. Kobak KA, Greist JH, Jefferson JW, et al. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacol 1998;136(3):205-216
150. Emmelkamp PMG, Visser S, Hoekstra RJ. Cognitive therapy vs exposure in vivo in the treatment of obsessive compulsive disorder. Cogn Ther Res 1988;12:103-114
151. McLean PD, Whittal ML, Thordarson DS, et al. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Consult Clin Psychol 2001;69(2):205-214
152. Van Oppen P, De Haan E, Van Balkom AJ, et al. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav Res Ther 1995;33:379-390
153. Beck AT. Cognitive therapy and emotional disorders. International University Press; Meriden, NY; 1976
154. Reed GF. Obsessive-compulsive disorder: a cognitive/structural approach. Can Psychol 1983;24:169-180
155. Salkovskis PM. Obsessional-compulsive problems: a cognitive behavioral analysis. Behav Res Ther 1985;23:571-583
156. Creamer M. Cognitive interventions in the treatment of obsessive-compulsive disorder. Behav Change 1987;4:20-27
157. Freeston MH, Ladouceur R, Gagnon F, et al. Cognitive-behavioral treatment of obsessive thoughts: a controlled study. J Consult Clin Psychol 1997;65:405-413 (Pubitemid 27246781)
158. Cordioli AV, Heldt E, Bochi DB. Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. Psychother Psychosom 2003;72:211-216
159. Whittal ML, Thordarson DS, McLean PD. Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention. Behav Res Ther 2005;43:1559-1576
160. Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005;162:151-161
161. Van Oppen P, Van Balkom AJ, De Haan E, Van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry 2005;66:1415-1422
162. Christensen H, Hadzi P, Andrews G, Mattick R. Behavior therapy and tricyclic medication in the treatment of obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1987;55:701-711
163. Van Balkom AJLM, Van Oppen P, Wermeulen AWA, et al. Meta-analysis of the treatment of obsessive-compulsive disorder: a comparison of antidepressant, behavior and cognitive therapy. Clin Psychol Rev 1994;14:359-381
164. Starcevic V, Brakoulias V. Symptom subtypes of obsessive-compulsive disorder: are they relevant for treatment? Aust NZ J Psychiatry 2008;42(8):651-661
165. Prasko J, Paskova B, Zalesky R, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol Lett 2006;27:327-332
166. Sachdev PS, Loo CK, Mitchell PB, et al. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med 2007;37:1645-1649
167. Alonso P, Pujol J, Cardoner N, et al. Right prefrontal repetitive transcranial magnetic stimulation in bsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2001;158(7):1143-1145
168. Anderson D, Ahmed A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation. Case report. J Neurosurg 2003;98:1104-1108
169. Gabriels L, Cosyns P, Nuttin B, et al. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 2003;107:275-282
170. Nuttin BJ, Gabriels LA, Cosyns PR, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2003;52:1263-1274
171. Aouizerate B, Cuny E, Martin-Guehl C, et al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 2004;101:682-686
172. Sturm V, Lenartz D, Koulousakis A, et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsiveand anxiety-disorders. J Chem Neuroanat 2003;26:293-299 (Pubitemid 38077152)
173. Yaryura-Tobias JA, Stevens KP, Perez-Rivera R, et al. Negative outcome after neurosurgery for refractory obsessive-compulsive spectrum disorder. World J Biol Psychiatry 2000;1:197-203
174. Oliver B, Gascon J, Aparicio A, et al. Bilateral anterior capsulotomy for refractory obsessive-compulsive disorders. Stereotact Funct Neurosurg 2003;81:90-95
175. Dougherty DD, Baer L, Cosgrove GR, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry 2002;159:269-275
176. Kim CH, Chang JW, Koo MS, et al. Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand 2003;107:283-290
177. Montoya A, Weiss AP, Price BH, et al. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. Neurosurgery 2002;50:1043-1052
178. Woerdeman PA, Willems PW, Noordmans HJ, et al. Frameless stereotactic subcaudate tractotomy for intractable obsessive-compulsive disorder. Acta Neurochir (Wien) 2006;148:633-637
179. Maletzky B, McFarland B, Burt A. Refractory obsessive compulsive disorder and ECT. Convulsive Ther 1994;10:34-42
180. Lavin MR, Halligan P. ECT for obsessive-compulsive disorder and schizophrenia. Am J Psychiatry 1996;153:1652-1653
181. Thomas SG, Kellner CH. Remission of major depression and obsessive-compulsive disorder after a single unilateral ECT. J ECT 2003;19:50-51
182. Swedo SE, Leonard HL, Mittleman BB, et al. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 1997;154(11):1630-1631
183. Marazziti D, Presta S, Pfanner C, et al. Immunological alterations in adult obsessive-compulsive disorder. Biol Psychiatry 1999;46(6):810-814
184. Marazziti D, Perez J, Cassano GB. Is obsessive-compulsive disorder caused by a second-messenger imbalance? CNS Spectr 2001;6(3):206-209
185. McDougle CJ. Update on pharmacologic management of OCD: agents and augmentation. J Clin Psychiatry 1997;58(12):11-17